Results 171 to 180 of about 5,542 (243)

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma. [PDF]

Medicine (Baltimore)
Yang J, Xu Q, Wu S.
europepmc   +1 more source

CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial. [PDF]

BMJ Open
Dai R, Zhang P, Cheng M, Bi F, Zhou J, Liu M.   +5 more
europepmc   +1 more source

Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process. [PDF]

Pharmaceuticals (Basel)
Shaifutdinov RR, Sinegubova MV, Vorobiev II, Prokhorova PE, Podkorytov AB, Orlova NA.   +5 more
europepmc   +1 more source

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Qi H, Huang Y, Zhang W, Li J, Wang T, Ying Y, Chen B, Miao F, Li Q.   +8 more
europepmc   +1 more source

Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study. [PDF]

Clin Pharmacol Drug Dev
Chow V, Winkle PJ, Mytych DT, Cao J, Barragan C, Colbert A, Gupta S, Radziszewski W, Franklin J.   +8 more
europepmc   +1 more source

Biosimilars and implications for pharmacy practice: Ready or not, here they come!

Pharmacy Practice, 2019
Hobbs AL, Crawford JP
doaj   +1 more source

A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB-14-X and Denosumab in Healthy Adult Males. [PDF]

Clin Transl Sci
Biver E, Body JJ, Sachdeva A, Študentová H, Nagy Z, Kun A, Horvát-Karajz K, Kiefer J, Pap T, Jókai E, Vasas FB, Seefried L.   +11 more
europepmc   +1 more source

The Impact of U.S. Tariffs on the Pharmaceutical Industry and Medicine Access in Europe: Challenges, Opportunities, and Future Outlook. [PDF]

Hosp Pharm
Castellana E, Chiappetta MR.
europepmc   +1 more source

Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and Safety. [PDF]

Adv Ther
Schmalzing M, Askari A, Girolomoni G, Perez-Coleman JCV, Salvati C, Bachinskaya E.   +5 more
europepmc   +1 more source